Puma Biotechnology vs Zymeworks
PBYI and ZYME side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How PBYI and ZYME compare
Zymeworks is the larger company, worth 4.9 times as much as Puma Biotechnology ($2.1B against $417M).
On earnings, Puma Biotechnology is cheaper: it trades at 17.6× trailing earnings, against 55.9× for Zymeworks.
Zymeworks grew revenue faster over the last twelve months (97.8% versus 9.4% for Puma Biotechnology).
Zymeworks keeps more of each dollar of sales as profit, with a net margin of 16.3% compared with 10.3% at Puma Biotechnology.
Puma Biotechnology scores higher on the StockData Score (14 against 10 for Zymeworks), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | PBYI | ZYME |
|---|---|---|
| Size and price | ||
| Market cap | $417M | $2.1B |
| Share price | $8.08 | $29.07 |
| Change, 1 year | 70.8% | 61.1% |
| Change, 5 years | 136% | 46.7% |
| Beta (5Y) | 0.98 | 0.84 |
| Employees | 179 | 264 |
| StockData Score | ||
| Total score | 14 (better) | 10 |
| Valuation score | 2 (better) | 0 |
| Growth score | 2 (better) | 1 |
| Performance score | 5 (better) | 4 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 17.6× (better) | 55.9× |
| P/S | 1.8× (better) | 7.8× |
| P/B | 2.8× (better) | 8.0× |
| EV/EBITDA | 8.7× (better) | 44.4× |
| P/FCF | 9.1× | – |
| FCF yield | 11.0% (better) | −5.5% |
| Fair value | $8.77 | $12.06 |
| Margin of safety | 7.8% (better) | −141% |
| Growth | ||
| Revenue growth (TTM) | 9.4% | 97.8% (better) |
| Revenue growth, 5Y average | 0.29% | 22.2% (better) |
| Net income growth (TTM) | −35.6% | – |
| EPS growth (TTM) | −37.8% | – |
| Profitability | ||
| Gross margin | 73.6% | – |
| Operating margin | 11.3% | 16.6% (better) |
| Net margin | 10.3% | 16.3% (better) |
| FCF margin | 19.9% (better) | −42.4% |
| Return on equity | 18.2% (better) | 15.0% |
| Return on invested capital | 38.7% (better) | 21.4% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Net debt / EBITDA | −2.77 | – |
| Interest coverage | 12.9× | – |
| Current ratio | 3.03 | 3.30 (better) |
| Altman Z-score | −2.14 | 0.87 (better) |
| Piotroski F-score | 8 (better) | 6 |
| Dividends and buybacks | ||
| Buyback yield | – | 8.0% |
| Shareholder yield | 0.00% | 8.0% (better) |
| Ownership | ||
| Held by institutions | 74.9% | 98.1% |
| Held by insiders | 18.9% | 58.9% |
| Insider net buying, 12 months | −$2.0M (better) | −$5.0M |
| Short interest, % of float | 10.3% | 20.3% |
Go deeper
- PBYI stock overview
- PBYI income statement
- PBYI valuation and score
- ZYME stock overview
- ZYME income statement
- ZYME valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.